Bone Biologics Corporation

Equities

BBLG

US0980705018

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:30:00 2024-04-29 pm EDT 5-day change 1st Jan Change
1.565 USD +2.29% Intraday chart for Bone Biologics Corporation -2.19% -65.38%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Bone Biologics Corporation Reports Progress with NB1 Clinical Program CI
Bone Biologics Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Bone Biologics Corporation Announces Board Changes CI
Bone Biologics Corporation Announces the Resignation of Erick Lucera as Director CI
Bone Biologics' 1-for-8 Reverse Stock Split Takes Effect Wednesday MT
Bone Biologics Closes Common Stock Offering; Shares Fall After Hours MT
Bone Biologics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Bone Biologics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Top Midday Decliners MT
Top Premarket Decliners MT
Bone Biologics Prices Underwritten Public Offering of Common Stock MT
Bone Biologics Files Registration for Planned Stock Offering at Target Price of $5.40 a Share MT
Bone Biologics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Certain Warrants of Bone Biologics Corporation are subject to a Lock-Up Agreement Ending on 6-APR-2023. CI
Certain Options of Bone Biologics Corporation are subject to a Lock-Up Agreement Ending on 6-APR-2023. CI
Certain Common Stock of Bone Biologics Corporation are subject to a Lock-Up Agreement Ending on 6-APR-2023. CI
Bone Biologics Corporation Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Bone Biologics Corporation Auditor Raises 'Going Concern' Doubt CI
Top Premarket Decliners MT
Bone Biologics Corporation Resigns Stephen Laneve as Director CI
Bone Biologics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
EF Hutton Initiates Bone Biologics With Buy Rating, $2.25 Price Target MT
Top Midday Decliners MT
Bone Biologics Prices $5.1 Million Securities Offering; Shares Plunge MT
Bone Biologics Corporation(NasdaqCM:BBLG) added to S&P TMI Index CI
Chart Bone Biologics Corporation
More charts
Bone Biologics Corporation is a developer of orthobiologic products for spine fusion markets. It is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications. It is a medical device company that is focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with demineralized bone matrix (DBM), is an osteopromotive recombinant protein that provides target specific control over bone regeneration. Its platform technology is its NELL-1, a proprietary skeletal specific growth factor which is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
More about the company